EP2425824

EURO-CELTIQUE S.A.
Application Number
EP11177516A
Filing Date
Apr 4, 2003
Status
Revoked
Feb 7, 2020
Grant Date
May 10, 2017
External Links
Slate, Register

Biblio Summary

The patent EP2425824B1 was granted on May 10, 2017 by Euro-Celtique S.A. The patent is currently Revoked.

The table below shows 14 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA, K.S.Feb 9, 2018ADMISSIBLE
TEVAFeb 8, 2018ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIES LTDFeb 8, 2018ADMISSIBLE
INTAS PHARMACEUTICALS LTD.Feb 5, 2018ADMISSIBLE
STADAJan 17, 2018ADMISSIBLE
STADA ARZNEIMITTEL AGJan 17, 2018ADMISSIBLE
G. L. PHARMA GMBHNov 9, 2017ADMISSIBLE
ETHYPHARMNov 7, 2017ADMISSIBLE
ACINO PHARMA AGJul 3, 2017ADMISSIBLE
KRKA, D.D., NOVO MESTOJun 9, 2017ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPE LTDMay 29, 2017ADMISSIBLE
DEVELCO PHARMA SCHWEIZ AGMay 11, 2017ADMISSIBLE
HEXAL AG / SANDOZ INTERNATIONAL GMBHMay 11, 2017ADMISSIBLE
SANDOZMay 11, 2017ADMISSIBLE

The table below shows the patents of Euro-Celtique S.A. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3578173Dosage Form Containing Oxycodone And NaloxoneOct 26, 20225
EP2568967Pharmaceutical Compositions Comprising Hydromorphone And NaloxoneJul 27, 20222
EP2706982Intranasal Pharmaceutical Dosage Forms Comprising NaloxoneMar 10, 20211

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.